



Resource planning for guideline development

Lessons learned in the German Guideline Program in Oncology


Markus Follmann, Annika Thiel, Cathleen Muche Borowski, Alexander Nast












Disclosure of Interests (last 3 years)

Markus Follmann

I certify that, to the best of my knowledge, no aspect of my current personal or professional situation might reasonably be expected to affect significantly my views on the subject on which I am presenting.



Background:



Aktueller Stand und Perspektiven


Rationale

- need for quality improvement in cancer care
- need for better knowledge transfer
- need for a common basis to improve networking of quality initiatives

 Nationaler Krebsplan
- German National Cancer Plan

www.bmg.bund.de


→GGPO was launched 2008, setting the goal to develop and implement clinical practice guidelines (CPGs) in oncology by:




Background:


GGPO OBJECTIVES

- supporting CPG development by scientific medical societies
- provie independent funding G development
- improving methodological quality of CPGs
- improving implementation and evaluation by
 - patient guidelines
 - short / long / pocket versions of CPGs
 - performance measures / quality indicators
- consolidating the network of quality initiatives



Organizational structure:






GGPO 2008: to be created

- Application process
- Ressource planing Matrix
- > Can we learn from other insitutions?





Any published data?

Sporadic data from German Guideline Projects

A. Nast, JDDG 2008 (Therapy of Psoriasis vulgaris)

Some G-I-N conference abstracts


J. Vlayen, Poster GIN Conference 2008


at this years conference: s. Poster P055


Julia Koepp et al.: Financing of Clinical Practice Guidelines (CPG) – what do we really know?

→No helpful articles via PubMed

Application processs








GGPO Matrix for estimating costs

Re	quested duration of funding: x years						
St	aff appropriations:						
-	 Name of the position, extent of the position in %, compensation group, duration (description of work profile) 						
-	 Ex: Research assistant, 50% position, TV-L E 13, for 3 years (system search, selection and appraisal of evidence) 						
lin	vestment funds (non-recurring):						
-	Device		€				
-	Device		€				
			€SUM				
Fu	nds for consumables:						
-	For	p. a.	€				
-	For	p. a.	€				
	p. a.		€SUM				


Travel expenses:						
For	p. a.	ϵ				
For	p. a.	€				
p. a.		€SUM				
Expenses for Consensus Conferences (room rental, accommodation, moderation, TED voting system, etc):						
For	p. a.	ϵ				
For	p. a.	€				
p. a.		€SUM				
Funds for external assignments (cost estimate required):						
e.g. providing evidence reports for defined KQ	p. a.	ϵ				
/quality indicators	p. a.	€				
	p. a.	€SUM				
	for p. a. spenses for Consensus Conferences (room rental Divoting system, etc): for for p. a. unds for external assignments (cost estimate recond):	for p. a. for p. a. p. a. p. a. penses for Consensus Conferences (room rental, accommod voting system, etc): for p. a. for p. a. p. a. p. a. inds for external assignments (cost estimate required): e.g. providing evidence reports for defined KQ p. a. e.g. development of patient guidelines /quality indicators p. a.				



GGPO Matrix for estimating costs


Labor	Meeting / Travel	Ext. Evidence reports	Other
Scientist (physician statistician)	Travel expenses	For selected key questions; subcontracting external agencies	Costs for searches, literature
Information specialist	Accommo- dation		Translations
Secretary	Technical stuff		Software
Students	Moderation		Conference calls
	Room rental		QI, Patient guidelines*

^{*} approx. 5.000 € QI, 17.000 € Patientguidelines




GGPO guideline development costs

CPG topic	duration (y)	labor	Travel Accom Meetings	Ext Evidence	other + QI + PLL	Sum
Hodgkin	2	121.800	79.620	0	3.000	204.420
Ovar	1,5	37.000	46.650	40.000	11.500	135.150
oral cavity	2	36.000	56.650	60.000	18.000	170.650
palliative $N=13$						
cervix dg th	Range: 135.150 - 370.100 €					
esophagus	Mean: 228.462 €					
cervix preventi renal cell ca	→ ex ante calculations!					
psychooncology	2	70.800	37.000	35.000	5.000	147.800
gastric cancer	2	75.750	94.500	32.332	11.000	213.582
skin cancer prev	2	132.400	72.400	0	17.525	222.325
melanoma	3	169.900	94.000	0	11.000	274.900
НСС	2	92.400	83.700	0	6.500	182.600
		1.414.540	925.220	417.988	211.785	2.969.533



GGPO guideline development costs


Amendments	labor	Travel Accom Meeting	gs Ext Evidence	other + QI + PLL	Sum
gastric cancer	Post hoc → amendements!				
нсс	'ex ante'Mean: 228.462 €				
colorectal	'adjusted' Mean: 256.643 €				
psychooncology	35.400	59.500	16.600	22.335	133.835
skin cancer prev	0	0	54.051	19.081	73.132
	50.750	59.500	170.651	85.931	366.832





GGPO Matrix for estimating costs

Labor	Meeting / Travel	Ext. Evidence reports	Other
Scientist (physician statistician)	Travel expenses	For selected key questions; subcontracting external agencies	Costs for searches, literature
Information specialist	Accommo- dation		Translations
Secretary	Technical stuff		Software
Students	Moderation		Conference calls
	Room rental		QI, Patient guidelines*

^{*} approx. 5.000 € QI, 17.000 € Patientguidelines







Conclusions:

GGPO is still learning!


Standardized financial schemes for GD are helpful for funder and GDG

The better the concrete project planning the more realistic the finance plan

Main part are labor costs and travel / acc. expenses

The correlation between Invested money and reached guideline quality should be considered (the more the better?)

Cost saving aspects should be kept in mind




Options for cost savings:

Keep the stuff working in the GDG

Develop a reasonable update strategy

Consider cost sparing like international cooperation

Foster national networks



Points to discuss within GIN:

Are costs of guideline development a relevant topic for GIN members?

Should we report that in a standardized way to allow comparisons? (units like e.g. costs per PICO question)

Can we discuss cost saving aspects together?



Thank you!

